NCM · Medical - Devices
LNSR (LNSR) Stock
$5.25
-1.87%
NCM: LNSR
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Zacks · Jul 2, 2026
How The LENSAR (LNSR) Story Is Shifting After The Failed Deal And New $10 Target
Simply Wall St. · Jun 4, 2026
Lensar (LNSR) Q1 2026 Earnings Transcript
Motley Fool · Jun 1, 2026
Lensar (LNSR) Q4 2025 Earnings Transcript
Motley Fool · Jun 1, 2026
LENSAR Q1 Earnings Call Highlights
MarketBeat · May 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held21.53%
Institutions Held52.01%
Institutions Float Held66.28%
Peer Comparison
About LNSR
LNSR is led by CEO Nicholas T. Curtis, employs 140 people, headquartered in US, publicly traded since 2020.
LNSR stock trades at $5.25 with a market capitalization of $63.55M. The stock is valued at a price-to-earnings (P/E) ratio of 6.53, price-to-book of 3.17, price-to-sales of 1.34. Over the past 52 weeks the stock has ranged between $5.06 and $13.47, and currently trades 61.0% below its 52-week high.
On profitability, LNSR generates a return on equity (ROE) of -514.92%, return on capital employed of -34.18%, an operating margin of -43.10%, a net profit margin of 50.94%.